

**RECEIVED
CENTRAL FAX CENTER
OCT 31 2006**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GILBERT and WAKARCHUK

Application No.: 10/820,536

Filed: April 7, 2004

For: NUCLEIC ACIDS ENCODING
SIALYLTRANSFERASES FROM C.
JEJUNI

Customer No.: 20350

Confirmation No. 8839

Examiner: Sheridan Swope

Technology Center/Art Unit: 1656

TERMINAL DISCLAIMER

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Petitioner, National Research Council of Canada, Inc., is the owner of 100 percent interest in the instant application. Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of U.S. Patent No. 6,669,705 (filed March 21, 2001) and any patent granted on pending US Application Number 10/734,719 (filed December 11, 2003).

U.S. Patent No. 6,669,705, US Application Number 10/734,719 and the instant application were commonly owned at that time of invention of the subject matter claimed in U.S. Patent No. 6,669,705 and any patent granted on pending US Application Number 10/734,719. Petitioner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and U.S. Patent No. 6,669,705 or any patent granted on pending US Application Number 10/734,719 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

11/01/2006 TL0111 00000036 201430 10820536

01 FC:1814 130.00 DA

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as deemed in 35 U.S.C. 154 to 156 and 173 of a patent granted from U.S. Patent No. 6,669,705 or a patent granted from any patent granted on pending US Application Number 10/734,719, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such patent expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned (whose title is supplied below) is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 26 October 2006

By: Marielle Piché
Name: Marielle Piché

Title: Secretary General, EXECUTIVE OFFICES
Secretary General, Executive Offices
Secretariat

Executive Offices
1200 Montreal Road
M-58 Room W-312
Ottawa, ON K1A 0R6